Roksana Grzeszczak

Roksana Grzeszczak

Auto-generated profile, based on publicly available information

Roksana Grzeszczak

Oddział Internistyczno-Kardiologiczny z Pododdziałem Intensywnego Nadzoru Internistyczno-Kardiologicznego, Szpital Wojewódzki w Poznaniu, Wielkopolskie Centrum Specjalistyczne, Polska

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Medycyna Nowożytna
Verified
Journal Article
Closed access
PDF file
AFAleksandra Fałczyńska
Aleksandra Fałczyńska
MGMaksymilian Grabarczyk
Maksymilian Grabarczyk
AGAgnieszka Głownia
Agnieszka Głownia
EBEmilia Bachoń
Emilia Bachoń
ABAleksandra Balak
Aleksandra Balak
KPKatarzyna Pekacka-Falkowska
Katarzyna Pekacka-Falkowska
Background: Plica as a disease entity appeared fi rst in the 13th century. Its aetiology is still unknown and not fully understood. Being, in fact, an irreversible condition of tangling and felting the hair, its origin was interpreted in various ways, from religious ones, through lack of hygiene to mental illness. Although p. polonica originates from Eastern and Central Europe, and p. neuropathica, typical of Indian people, was fi rst described in England, many characteristics connect these two conditions. Aim and Objectives: The study aimed to review the plica species over the centuries and to compare p. neuropathica and p. polonica. Materials and Methods: PubMed and Google Scholar databases were searched for medical articles, books and case studies on plica published up 1884 to 2020. We conducted a systematic and critical review of the literature to compare p. polonica and p. neuropathica. Results: Plica polonica and Plica neuropathica are the same disease entity. Conclusion: The variety of names and interpretations of the disease has made plica a condition still to be fully explained.

21 November 2025 in Aktualności Neurologiczne
Verified
Journal Article
Open access
PDPrzemysław Robert Dalski-Szeląg
Przemysław Robert Dalski-Szeląg
RGRoksana Grzeszczak
Roksana Grzeszczak
MZMilena Zaremba
Milena Zaremba
MGMagdalena Grabińska
Magdalena Grabińska
WSWojciech Mikołaj Szkudlarek
Wojciech Mikołaj Szkudlarek
MGMaksym K. Gmur
Maksym K. Gmur
Autoimmune diseases of the nervous system often cause neuropsychiatric symptoms, which can both herald the disease and indicate its exacerbation. This paper discusses autoimmune diseases of the nervous system in which neuropsychiatric symptoms occur particularly frequently or are especially severe, such as systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, Hashimoto’s encephalopathy, Guillain–Barré syndrome, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), and myasthenia gravis, with particular emphasis on their neuropsychiatric symptoms. In systemic lupus erythematosus, neuropsychiatric symptoms affect 30–40% of patients and may include cognitive impairments, psychosis, headaches, mood disorders, and others. Hashimoto's encephalopathy is a rare but serious disease requiring rapid immunosuppressive intervention, manifesting with cognitive dysfunction, seizures, productive symptoms, mood changes, and more. Multiple sclerosis, in addition to the neurological symptoms typical for disease relapses, also causes symptoms such as fatigue affecting about 80% of patients, depression, anxiety, and cognitive dysfunctions. Myasthenia gravis, besides its typical symptoms, often also features neuropsychiatric symptoms such as chronic fatigue, anxiety, and sleep disorders. Neuropsychiatric symptoms of autoimmune diseases of the nervous system, particularly depression, cognitive impairments, anxiety, psychosis, but also others, significantly reduce patients quality of life, and early identification of these symptoms is crucial not only for improving quality of life but also often for enhancing patient prognosis and reducing neurological complications.

3 January 2026 in Quality in Sport
Verified
Journal Article
Open access
RGRoksana Grzeszczak
Roksana Grzeszczak
AFAleksandra Fałczyńska
Aleksandra Fałczyńska
ABAleksandra Balak
Aleksandra Balak
WSWeronika Szkudlarek
Weronika Szkudlarek
KRKatarzyna Rotte
Katarzyna Rotte
IPIgor Piotrowski
Igor Piotrowski
Celiac disease (CD), also known as gluten-sensitive enteropathy, is the most common autoimmune disorder in today’s society. CD is associated with both human leukocyte antigen (HLA) and non-HLA genes. It often coexists with other autoimmune diseases, such as juvenile diabetes and thyroid disease. Diagnosis often relies on biopsy results, but serological tests are also very useful when screening patients suspected of having CD. Although our knowledge of celiac disease seems thorough, the pathogenesis of refractory celiac disease (RCD) is still under research. Treating RCD can be challenging, and it is crucial to provide care in experienced tertiary centers. Treatment may involve dietary and pharmacological approaches, depending on the type of RCD. This reduces the risk of disease progression and alleviates the symptoms. Investigations into other innovative treatment methods are ongoing.